Profectus BioSciences, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Profectus BioSciences, Inc. – Product Pipeline Review – 2016’, provides an overview of the Profectus BioSciences, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Profectus BioSciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Profectus BioSciences, Inc.

The report provides overview of Profectus BioSciences, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Profectus BioSciences, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Profectus BioSciences, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Profectus BioSciences, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Profectus BioSciences, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Profectus BioSciences, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Profectus BioSciences, Inc. Snapshot 7

Profectus BioSciences, Inc. Overview 7

Key Information 7

Key Facts 7

Profectus BioSciences, Inc. - Research and Development Overview 8

Key Therapeutic Areas 8

Profectus BioSciences, Inc. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Combination Treatment Modalities 13

Pipeline Products - Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Profectus BioSciences, Inc. - Pipeline Products Glance 16

Profectus BioSciences, Inc. - Clinical Stage Pipeline Products 16

Phase I Products/Combination Treatment Modalities 16

Profectus BioSciences, Inc. - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Profectus BioSciences, Inc. - Drug Profiles 19

(Ebola + Marburg) (monovalent) vaccine 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

(Ebola + Marburg) (trivalent) vaccine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

HIV [strain C1086] vaccine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

HIV-1 vaccine 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

IHV-001 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

(nipah + hendra) vaccine 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

chikungunya vaccine 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

equine encephalitis vaccine 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

hepatitis B vaccine 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

hepatitis C vaccine 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

human papillomavirus (7-valent) vaccine 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

M-102.4 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

herpes simplex virus 2 vaccine 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Lassa fever vaccine 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

respiratory syncytial virus vaccine 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Profectus BioSciences, Inc. - Pipeline Analysis 40

Profectus BioSciences, Inc. - Pipeline Products by Target 40

Profectus BioSciences, Inc. - Pipeline Products by Route of Administration 41

Profectus BioSciences, Inc. - Pipeline Products by Molecule Type 42

Profectus BioSciences, Inc. - Recent Pipeline Updates 43

Profectus BioSciences, Inc. - Dormant Projects 45

Profectus BioSciences, Inc. - Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Profectus BioSciences, Inc., Key Information 7

Profectus BioSciences, Inc., Key Facts 7

Profectus BioSciences, Inc. – Pipeline by Indication, 2016 10

Profectus BioSciences, Inc. – Pipeline by Stage of Development, 2016 11

Profectus BioSciences, Inc. – Monotherapy Products in Pipeline, 2016 12

Profectus BioSciences, Inc. – Combination Treatment Modalities in Pipeline, 2016 13

Profectus BioSciences, Inc. – Partnered Products in Pipeline, 2016 14

Profectus BioSciences, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 15

Profectus BioSciences, Inc. – Phase I, 2016 16

Profectus BioSciences, Inc. – Preclinical, 2016 17

Profectus BioSciences, Inc. – Discovery, 2016 18

Profectus BioSciences, Inc. – Pipeline by Target, 2016 40

Profectus BioSciences, Inc. – Pipeline by Route of Administration, 2016 41

Profectus BioSciences, Inc. – Pipeline by Molecule Type, 2016 42

Profectus BioSciences, Inc. – Recent Pipeline Updates, 2016 43

Profectus BioSciences, Inc. – Dormant Developmental Projects,2016 45

Profectus BioSciences, Inc., Other Locations 46

List of Figures

List of Figures

Profectus BioSciences, Inc. – Pipeline by Top 10 Indication, 2016 9

Profectus BioSciences, Inc. – Pipeline by Stage of Development, 2016 11

Profectus BioSciences, Inc. – Monotherapy Products in Pipeline, 2016 12

Profectus BioSciences, Inc. – Combination Treatment Modalities in Pipeline, 2016 13

Profectus BioSciences, Inc. – Pipeline by Top 10 Target, 2016 40

Profectus BioSciences, Inc. – Pipeline by Top 10 Molecule Type, 2016 42

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports